Pharming announces completion of enrolment in Phase II/III study with leniolisib for activated PI3K delta syndrome
Pharming announces the successful completion of patient enrolment in the pivotal Phase II/III triple-blind, randomized, placebo-controlled study of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS).
With completion of enrolment, we move one step closer to making this medicine available for APDS patients around the world.- Anurag Relan - Chief Medical Officer
Would you like to switch to another language? Click here to visit our English website.